Announcement of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. on the share repurchase of the top ten shareholders and the shareholdings of the top ten shareholders without selling restrictions
Securities code: 688506 Securities abbreviation: Baili Tianheng Announcement number: 2026-004 Sichuan Baili Tianheng Pharmaceutical Co., Ltd.
Announcement on the shareholdings of the top ten shareholders on share repurchase and the top ten shareholders without selling restrictions
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents in accordance with the law.
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the fifth meeting of the fifth board of directors on December 30, 2025, and reviewed and approved the "Proposal on the Plan to Repurchase the Company's Shares through Centralized Bidding Transactions". For details, please refer to the company's announcement on December 31, 2025. "Sichuan Baili Tianheng Pharmaceutical Co., Ltd.'s Plan for Repurchasing Shares through Centralized Bidding Transactions" was published daily on the website of the Shanghai Stock Exchange (www.sse.com.cn) (Announcement No.: 2025-093).
In accordance with the "Share Repurchase Rules of Listed Companies", "Shanghai Stock Exchange Self-Discipline Supervision Guidelines for Listed Companies No. 7 - Repurchase of Shares" and other relevant regulations, the names, shareholding amounts and proportions of the top ten shareholders and the top ten shareholders without sales restrictions on the trading day before the resolution of the fifth meeting of the fifth session of the Board of Directors of the company is announced (i.e. December 30, 2025) are now announced as follows:
1. Shareholding status of the company’s top ten shareholders
Total number of holdings Ratio to total share capital Serial number Name of shareholder
(Share) Example (%) 1 Zhu Yi 298,159,400 72.22 2 OAP III (HK) Limited 28,527,171 6.91 3 Zhang Suya 9,575,543 2.32 Industrial and Commercial Bank of China Co., Ltd.-China Europe Medical
4 5,426,546 1.31 Medical Health Mixed Securities Investment Fund
China Merchants Bank Co., Ltd.-China Securities Securities Exchange
5 GEM 50-component trading open-end index securities investment fund 3,185,228 0.77 investment fund
Industrial and Commercial Bank of China Co., Ltd.-E Fund
6 SSE Science and Technology Innovation Board 50-Component Trading Open Index 3,031,065 0.73 Securities Investment Fund
7 Hong Kong Securities Clearing Company Limited 3,023,585 0.73China Construction Bank Corporation-China Universal
8 1,605,640 0.39
Innovative medicine theme hybrid securities investment fund
Industrial Bank Co., Ltd.-Yongying Pharmaceutical Innovation
9 1,420,264 0.34Xinzhixuan Hybrid Sponsored Securities Investment Fund
CITIC Securities-Industrial Bank-CITIC Securities Baili
10 Tianheng employees participated in the strategic placement of the Science and Technology Innovation Board 1,408,868 0.34
property management plan
2. Shareholding status of the company’s top ten shareholders without selling restrictions
Total number of shares held No. of streams with no selling conditions Shareholder name
(Share) Share ratio (%) 1 OAP III (HK) Limited 28,527,171 27.73 2 Zhang Suya 9,575,543 9.31
Industrial and Commercial Bank of China Co., Ltd.-China European Medicine
3 3,570,669 3.47 Medical Health Mixed Securities Investment Fund
China Merchants Bank Co., Ltd.-China Securities Securities Exchange
4 GEM 50-component trading open-ended index securities investment 3,185,228 3.1
capital fund
5 Hong Kong Securities Clearing Company Limited 3,023,585 2.94
Industrial and Commercial Bank of China Co., Ltd.-E Fund
6 SSE Science and Technology Innovation Board 50-Component Trading Open Index 2,376,902 2.31 Securities Investment Fund
Industrial Bank Co., Ltd.-Yongying Pharmaceutical Innovation
7 1,420,264 1.38 New Smart Choice Hybrid Sponsored Securities Investment Fund
China Construction Bank Corporation-China Universal
8 1,416,366 1.38 Innovative Medical Theme Hybrid Securities Investment Fund
CITIC Securities-Industrial Bank-CITIC Securities Baili
9 Tianheng employees participated in the strategic placement of collective capital on the Science and Technology Innovation Board 1,408,868 1.37 Asset Management Plan
Industrial and Commercial Bank of China Co., Ltd.-Huataibai
10 Rui CSI 300 Trading Open Index Securities Investment 1,374,927 1.34
capital fund
Announcement is hereby made.
Board of Directors of Sichuan Baili Tianheng Pharmaceutical Co., Ltd.
January 9, 2026